MX2022003823A - Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof. - Google Patents

Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof.

Info

Publication number
MX2022003823A
MX2022003823A MX2022003823A MX2022003823A MX2022003823A MX 2022003823 A MX2022003823 A MX 2022003823A MX 2022003823 A MX2022003823 A MX 2022003823A MX 2022003823 A MX2022003823 A MX 2022003823A MX 2022003823 A MX2022003823 A MX 2022003823A
Authority
MX
Mexico
Prior art keywords
sub
compositions
subtypes
methods
gaba
Prior art date
Application number
MX2022003823A
Other languages
Spanish (es)
Inventor
Andrew D Levin
Neil Buckley
Original Assignee
Eliem Therapeutics Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eliem Therapeutics Uk Ltd filed Critical Eliem Therapeutics Uk Ltd
Publication of MX2022003823A publication Critical patent/MX2022003823A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

The invention provides compositions containing isomerically pure forms of neurosteroids that permit preferential modulation of different subtypes of GABA<sub>A</sub> receptors, such as preferential modulation of α4β3δ GABA<sub>A</sub> receptors over α1β2γ2 GABA<sub>A</sub> receptors. The invention also provides methods of treating GABA<sub>A</sub> disorders using such compositions.
MX2022003823A 2019-09-30 2020-09-23 Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof. MX2022003823A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962907763P 2019-09-30 2019-09-30
PCT/US2020/052167 WO2021067089A1 (en) 2019-09-30 2020-09-23 Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022003823A true MX2022003823A (en) 2022-08-17

Family

ID=75338529

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003823A MX2022003823A (en) 2019-09-30 2020-09-23 Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof.

Country Status (9)

Country Link
EP (1) EP4135710A4 (en)
JP (1) JP2022552788A (en)
KR (1) KR20220103707A (en)
CN (1) CN115087450A (en)
BR (1) BR112022006085A2 (en)
CA (1) CA3159087A1 (en)
IL (1) IL291835A (en)
MX (1) MX2022003823A (en)
WO (1) WO2021067089A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021252314A1 (en) * 2020-06-08 2021-12-16 Eliem Therapeutics, Inc. Methods of treating female health conditions related to sex hormones
WO2024020953A1 (en) * 2022-07-28 2024-02-01 湖南科益新生物医药有限公司 Steroid compound for treating central nervous system disease, method for preparing same, and use and pharmaceutical composition thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US9512165B2 (en) * 2013-04-17 2016-12-06 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
CN117024501A (en) * 2014-10-16 2023-11-10 萨奇治疗股份有限公司 Compositions and methods for targeting CNS disorders
US20190321375A1 (en) * 2016-10-14 2019-10-24 Marinus Pharmaceuticals, Inc. Method of administering a neurosteroid to effect electroencephalographic (eeg) burst suppression
WO2020210116A1 (en) * 2019-04-08 2020-10-15 Athenen Therapeutics, Inc. Steroids with altered pharmacokinetic properties and methods of use thereof

Also Published As

Publication number Publication date
BR112022006085A2 (en) 2023-03-14
EP4135710A4 (en) 2023-12-06
EP4135710A1 (en) 2023-02-22
WO2021067089A1 (en) 2021-04-08
CA3159087A1 (en) 2021-04-08
KR20220103707A (en) 2022-07-22
CN115087450A (en) 2022-09-20
JP2022552788A (en) 2022-12-20
IL291835A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
MX2022003823A (en) Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof.
MX2023004593A (en) Tyk2 inhibitors and uses thereof.
MX2023003989A (en) Compounds, compositions and methods.
MX2022005232A (en) Small molecule degraders of helios and methods of use.
UY32152A (en) PROSTAGLANDINA D2 RECEPTORS HETEROARIL ANTAGONISTS
MX2021012216A (en) Stat degraders and uses thereof.
UA99936C2 (en) Biaryl substituted azabicyclic alkane derivatives
EA201891615A1 (en) SUBSTITUTED THIOGIDANTOIN DERIVATIVES AS ANTAGONISTS ANDROGEN RECEPTOR
TW200621244A (en) Modulators of muscarinic receptors
NZ743651A (en) Benzothiophene-based selective estrogen receptor downregulators
WO2015108988A3 (en) Methods and compositions for modulating hormone levels
AR074369A1 (en) ANTI-UNC 5B ANTIBODIES (NETRINE RECEIVER) AND METHODS OF USE
CR20210607A (en) Natriuretic peptide receptor 1 antibodies and methods of use
MX2020006355A (en) Substituted pyrrolidine amides ii.
MX2021000759A (en) Further substituted triazolo quinoxaline derivatives.
PH12019550272A1 (en) Liver x receptors (lxr) modulators
SI3573620T1 (en) Compositions for the treatment of hypertension
MX2021014585A (en) Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease.
MX2023009060A (en) Gpr84 antagonists and uses thereof.
MX2023005408A (en) Compounds and their use in treatment of tachykinin receptor mediated disorders.
MX2022000203A (en) Sustained release compositions of endoxifen.
WO2018081168A3 (en) Benzothiophene-based selective mixed estrogen receptor downregulators
MX2023009059A (en) Gpr84 antagonists and uses thereof.
MX2022014220A (en) Calmodulin inhibitors, chk2 inhibitors and rsk inhibitors for the treatment of ribosomal disorders and ribosomapathies.
MX2019013700A (en) Compositions and methods for the treatment of complications and disorders relating to von willebrand factor.